Sernova Biotherapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2026-02-05.
Sernova Biotherapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on February 5, 2026. The filing reports $345K sold. Its industry group is Biotechnology. It names James Parsons (Executive Officer), Jonathan Rigby (Chief Executive Officer and Director), Bernd Muehlenweg (Director) (SEC Form D, February 5, 2026).
Sell to companies like Sernova Biotherapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-02-05 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Sernova Biotherapeutics Inc.
Free to see. No signup.
More on the people and the money behind Sernova Biotherapeutics Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Sernova Biotherapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Sernova Biotherapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch Sernova Biotherapeutics Inc. →Get the full cited report on Sernova Biotherapeutics Inc.
What the filing shows about Sernova Biotherapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sernova Biotherapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Sernova Biotherapeutics Inc. See pricing
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $345K, on the same scale — one filing against the whole group's total, so it sits low by construction.
James Parsons is named as Executive Officer on the Form D that Sernova Biotherapeutics Inc. filed with the SEC on 5 February 2026, one of 9 people that filing names.
On the filing as: Executive Officer, Director.
Jonathan Rigby is named as Chief Executive Officer and Director on the Form D that Sernova Biotherapeutics Inc. filed with the SEC on 5 February 2026, one of 9 people that filing names.
Bernd Muehlenweg is named as Director on the Form D that Sernova Biotherapeutics Inc. filed with the SEC on 5 February 2026, one of 9 people that filing names.
John Brooks is named as Director on the Form D that Sernova Biotherapeutics Inc. filed with the SEC on 5 February 2026, one of 9 people that filing names.
David Paterson is named as Director on the Form D that Sernova Biotherapeutics Inc. filed with the SEC on 5 February 2026, one of 9 people that filing names.
Steven Sangha is named as Director on the Form D that Sernova Biotherapeutics Inc. filed with the SEC on 5 February 2026, one of 9 people that filing names.
Tanya Lewis is named as Director on the Form D that Sernova Biotherapeutics Inc. filed with the SEC on 5 February 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
David Burke is named as Vice President, Investor Relations on the Form D that Sernova Biotherapeutics Inc. filed with the SEC on 5 February 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Marylyn Rigby is named as Chief Communications Officer on the Form D that Sernova Biotherapeutics Inc. filed with the SEC on 5 February 2026, one of 9 people that filing names.
9 people named on the filing — 4 holding an executive role and 5 as directors only.
Named as of the 2026-02-05 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Sernova Biotherapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sernova Biotherapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sernova Biotherapeutics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Sernova Biotherapeutics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Sernova Biotherapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Sernova Biotherapeutics Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/sernova-biotherapeutics-inc-form-d-26000001